- Home
- HLI vs MRNA Comparison
HLI vs MRNA Comparison
Compare HLI & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HLI
- MRNA
- Stock Information
- Founded
- HLI 1972
- MRNA 2010
- Country
- HLI United States
- MRNA United States
- Employees
- HLI N/A
- MRNA 5800
- Industry
- HLI Investment Managers
- MRNA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HLI Finance
- MRNA Health Care
- Exchange
- HLI Nasdaq
- MRNA Nasdaq
- Market Cap
- HLI 13.7B
- MRNA 13.4B
- IPO Year
- HLI 2015
- MRNA 2018
- Fundamental
- Price
- HLI $195.94
- MRNA $34.15
- Analyst Decision
- HLI Buy
- MRNA Hold
- Analyst Count
- HLI 8
- MRNA 20
- Target Price
- HLI $202.57
- MRNA $46.76
- AVG Volume (30 Days)
- HLI 403.7K
- MRNA 9.3M
- Earning Date
- HLI 07-29-2025
- MRNA 08-01-2025
- Dividend Yield
- HLI 1.22%
- MRNA N/A
- EPS Growth
- HLI 41.61
- MRNA N/A
- EPS
- HLI 5.82
- MRNA N/A
- Revenue
- HLI $2,389,126,000.00
- MRNA $3,177,000,000.00
- Revenue This Year
- HLI $10.96
- MRNA N/A
- Revenue Next Year
- HLI $13.16
- MRNA $9.70
- P/E Ratio
- HLI $33.75
- MRNA N/A
- Revenue Growth
- HLI 24.80
- MRNA N/A
- 52 Week Low
- HLI $137.99
- MRNA $23.15
- 52 Week High
- HLI $198.78
- MRNA $125.68
- Technical
- Relative Strength Index (RSI)
- HLI 65.35
- MRNA 64.57
- Support Level
- HLI $191.39
- MRNA $30.88
- Resistance Level
- HLI $198.78
- MRNA $35.59
- Average True Range (ATR)
- HLI 3.60
- MRNA 1.48
- MACD
- HLI 0.10
- MRNA 0.11
- Stochastic Oscillator
- HLI 80.81
- MRNA 74.05
About HLI Houlihan Lokey Inc.
Houlihan Lokey Inc is an investment bank with expertise in mergers and acquisitions, capital markets, financial restructuring, valuation, and strategic consulting. The firm serves corporations, institutions, and governments world-wide with offices in the United States, Europe, and the Asia-Pacific region. The company operates in three segments. In the Corporate Finance business segment, it provides M&A and capital markets advisory services. Through the Financial Restructuring business segment, the company advises on some of the complex restructurings around the world. The Financial and Valuation Advisory Services business segment provides valuation and financial opinion, and financial and strategic consulting practices in the United States.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.